Topical apraclonidine is administered at a concentration of 1% for the prevention and treatment of post-surgicalintraocular pressure (IOP) elevation and 0.5% for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional reduction of IOP. One drop is usually added one hour prior to lasereye surgery and another drop is given after the procedure is complete.
Apraclonidine is indicated for the short-term adjunctive treatment of glaucoma for patients on maximally tolerated medical therapy who require additional reduction of IOP. These patients, who are treated with apraclonidine to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the intraocular pressure rises significantly.
Apraclonidine may be useful in the diagnosis ofHorner's syndrome. In Horner's syndrome, the sympathetic innervation to the pupillary dilator muscle is lost. The affected pupil is thus miotic and the pupillary dilator responds to denervation by increasing α1 receptors. Apraclonidine is useful in this case due to its weak α1-adrenergic properties. When applied to the denervated (and thus hyper-sensitive) pupillary dilator muscle, a super-normal dilatory response is generated in which the pupil dilates to a degree greater than that which would be seen in a non-denervated muscle. This causes the reversal ofanisocoria that is characteristic of Horner's.
Topical apraclonidine can also decrease IOP in glaucoma patients by increasing trabecular outflow, in a similar way toclonidine,[1] but without the cardiovascular side effects. Apraclonidine has been compared with other treatments such asbrimonidine andpilocarpine in preventing IOP spikes afterlaser trabeculoplasty.[2] The results did not show significant differences in the reduction of IOP for apraclonidine, when compared to brimonidine or pilocarpine.[2]
^Toris CB, Tafoya ME, Camras CB, Yablonski ME (March 1995). "Effects of apraclonidine on aqueous humor dynamics in human eyes".Ophthalmology.102 (3):456–461.doi:10.1016/S0161-6420(95)31000-7.PMID7891985.
Chen PL, Chen JT, Lu DW, Chen YC, Hsiao CH (June 2006). "Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients".Journal of Ocular Pharmacology and Therapeutics.22 (3):182–187.doi:10.1089/jop.2006.22.182.PMID16808679.
Aslanides M, Tsiklis NS, Ozkilic E, Coskunseven E, Pallikaris G, Jankov MR (June 2006). "The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients".Journal of Refractive Surgery.22 (6):585–588.doi:10.3928/1081-597X-20060601-11.PMID16805122.
Koc F, Kansu T, Kavuncu S, Firat E (March 2006). "Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients".Journal of Neuro-Ophthalmology.26 (1):25–29.doi:10.1097/01.wno.0000204648.79744.71.PMID16518162.S2CID45290834.
Garibaldi DC, Hindman HB, Grant MP, Iliff NT, Merbs SL (2006). "Effect of 0.5% apraclonidine on ptosis in Horner syndrome".Ophthalmic Plastic and Reconstructive Surgery.22 (1):53–55.doi:10.1097/01.iop.0000196322.05586.6a.PMID16418668.
Onal S, Gozum N, Gucukoglu A (2005). "Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification".Ophthalmic Surgery, Lasers & Imaging.36 (6):457–462.doi:10.3928/1542-8877-20051101-05.PMID16355950.
